|Bid||19.279 x 26300|
|Ask||19.451 x 25300|
|Day's Range||19.035 - 19.035|
|52 Week Range||11.708 - 19.473|
|PE Ratio (TTM)||-10.82|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Contract drug manufacturer and research company Albany Molecular Research Inc said on Tuesday it had agreed to be taken private by buyout firms Carlyle Group LP and GTCR LLC for about $922 million in cash. Clinical research organizations can prove to be lucrative investments for private equity firms.
Contract-drug manufacturer Albany Molecular Research Inc. said Tuesday that it has agreed to be acquired by private-equity firms Carlyle Group LP and GTCR LLC in a deal worth about $933.9 million.
Shares of Albany Molecular Research saw a handy gain on Tuesday after it was announced that the company signed a definitive agreement to be acquired.